Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $4.30, but opened at $4.66. Gyre Therapeutics shares last traded at $4.3980, with a volume of 119,359 shares trading hands.
Analyst Ratings Changes
A number of research analysts have recently weighed in on GYRE shares. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 6th. Wall Street Zen raised shares of Gyre Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Gyre Therapeutics in a report on Wednesday, November 4th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce”.
Gyre Therapeutics Stock Performance
The firm has a 50 day moving average price of $6.30 and a two-hundred day moving average price of $6.81. The company has a market cap of $497.03 million, a P/E ratio of -21.55 and a beta of 2.14.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.19. Gyre Therapeutics had a negative net margin of 14.80% and a negative return on equity of 7.39%. The firm had revenue of $32.93 million during the quarter, compared to the consensus estimate of $28.40 million. On average, sell-side analysts predict that Gyre Therapeutics, Inc. will post -0.61 EPS for the current fiscal year.
Hedge Funds Weigh In On Gyre Therapeutics
A number of large investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Gyre Therapeutics during the second quarter valued at $6,550,000. SBI Securities Co. Ltd. increased its holdings in shares of Gyre Therapeutics by 1.8% in the 3rd quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock worth $1,244,000 after buying an additional 2,967 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Gyre Therapeutics during the 2nd quarter worth $414,000. Dimensional Fund Advisors LP increased its stake in Gyre Therapeutics by 131.8% in the first quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock valued at $176,000 after acquiring an additional 14,365 shares during the last quarter. Finally, Deutsche Bank AG bought a new position in Gyre Therapeutics in the second quarter valued at $118,000. 23.99% of the stock is currently owned by institutional investors.
Gyre Therapeutics Company Profile
Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.
See Also
- Five stocks we like better than Gyre Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
